Ironically, the device was invented by a father of a child with asthma.
Sentiment: Strong Buy
Many of the 300 million people worldwide that suffer from asthma and many of the 210 million people worldwide that are affected by chronic obstructive pulmonary disease (COPD), do not have the strength to inhale medicines from traditional dry powder inhalers. Further, metered-dose inhalers require hand-breathing coordination (which often leads to less effective deposition of medication) while nebulizers require relatively long treatment times and their setup is cumbersome. Thus, it should not be surprising that as many as 80% of patients do not use their inhalers effectively.
Inspiro Medical has developed a novel dry powder drug delivery solution for pulmonary indications. Inspiro’s Inspiromatic can be programmed to achieve maximum effectiveness by delivering the prescribed amount of drugs to a targeted spot on the lungs. This is accomplished by a flow sensor embedded into the hand-held Inspiromatic taking into account the patient’s inhalation flow rates and breathing patterns as well as an active particle’s de-agglomeration mechanism.
During ill patient simulations, Inspiro delivered twice the amount of drugs compared with competing inhalers. With Inspiro Medical, even children, the elderly and the seriously ill can benefit by enhanced dry powder drug delivery without forceful inhalation.
The Inspiromatic is a sleek hand-held device that is cost effective in the sense that the drug formulation does not remain in the loading chamber. Also, a built-in data logger indicates whether or not a proper inhalation technique has been adhered to, which is crucial in ensuring that the appropriate amount of drugs are released. Finally, direct communications between the Inspiromatic and the physician is facilitated by USB and wireless connectivity.
Wondering, if they were to license out the device, how soon would they be able to do it?
This is going to be big time. Burn,as you know, I bought into ARRY for their ARRY-502 drug, and being an asthmatic and having a daughter with asthma, I am familiar with just about every drug and delivery devise that is out their. Using a spacer is often used so the medicine does not just blow to the back of the throat instead it enables the particles to go down to the lungs. Having a beeper and green/red light to indicate whether the medicine was delivered properly is revolutionary to say the least. Spiriva has a device where a pill is inserted into a device, you push a button and the device pokes a couple holes in the capsule then when you inhale, the pill spins real fast releasing the powder and it is inhaled. Symbicort has an inhalor that looks like the average inhaler, but on the top is a meter that tells counts down to how many inhalations are left. Inspiromatic looks to have all the bells and whistles and I am very intrigued. Licensing out the inhaler would offer the greatest short term revenue unless they have a product to go with it that is just as game changing.
You're right. Seems like we might be in for a bit more pain. JPM didn't really start things off very well for us today. WFC did ok. Market is confused on what to do right now. Jobless claims lower, more jobs added, overall economy surging, yet interest rates going lower, but borrowers not taking advantage and oil is rising. Thinking we could attribute some to tax selling and some to option expirations. Next week we have a short week, but I bet we see some traction after Easter. Glad to take advantage of these bargains and I am not worried. Next month this all will have reversed. BTW, I see BAC meeting expectations but C will miss badly. I still view C as a sub $5 stock that just decided to do a makeover by doing a reverse 1 for 10 split.
Well, I didn't plan on selling today, or or next week or month, so $3.83 close today is of little consequence. Nobody can call a bottom, but this is a great buying opportunity.
Thanks. Thinking shares would be higher if not for market wide sell off lately. Definitely oversold on what could be considered good news that it is safe to continue trials. I think this is a very good entry with little downside.
Well, if I'm wrong, I'm wrong. But I view the sell off is due to disappointment in Cometriq trial continuing and not halted. There has been no new news on lack of sales, running out of cash or stock dilution to be attributed to this sell off that is not exclusive to only EXEL.
In today at $3.44. So, trial on Cometriq (cabozantinib) was told to continue with trial and wasn't halted. Results should be out later this year anyway. Sales of Cometriq in 4th quarter was $4.3 million, and just a couple weeks ago the EU was on board for marketing Cometriq for thyroid cancer and has orphan drug status there as well. EXEL has partners and a pipeline with near term results coming. I'm in.
Burnanka, ok, I did a little research on EXEL and it looks good. Plenty of partners and though recent sell off could probably be viewed as a "knee-jerk" reaction because of the disappointment cabozantinib was recommended trials continue and not halted. Cometriq is already approved in US for Thyroid cancer but they want it good for prostate cancer too. Looks like results should be out later this year anyway, so just like OPK and ARRY...patience is a virtue. In with a starter position at $3.44
Burnaka, I have not checked into EXEL yet, but I will. I was about as close as you were on pulling the trigger on mnkd and missed the big move. Hard to believe ARRY is at $4, should be at least $5. I took a gamble on BZNE since most of the OPK insiders have large positions. Thinking OPK might go lower until Raladee news (why did they change the spelling?) I put some in YHOO yesterday at $33.67, prior to earnings next week, don't know when Alibaba IPO will happen, but should push to $40 on the announcement. Also added MU this week at $22.60, should easily be $32 with $3.25 eps.
Counting on some good news on a couple of the phase 3 studies/partnerships later this year, so added more today. Looking long term, $4.15 for ARRY is cheap.
Way oversold and should be at least a $5.00 stock right now. Good gains ahead when the market wide sell off is over.
Sentiment: Strong Buy
This is a portion of the Inquisitor from this morning..
"But some of our own readers have suggested another type of Brock Lesnar conspiracy theory. It’s claimed that Undertaker losing was a mistake or an accident. For evidence for this idea, they point to how Paul Heyman was freaking out while there was a delayed reaction with both the background music and color commentators. After all, it does seem odd how Daniel Bryan’s triumph was calculated to make the fans extremely happy, so why would Vince McMahon do something completely out of left field like this? After all, the WWE is a business and fans were walking out of the stadium after the match result and people on social media are talking about canceling their WWE Network subscription."
And 6 months from now, when the "commitment" period ends, and the newness wears off, you will see a bigger drop of subscriptions than you see signups. The live attendants is the bread and butter of WWE. From what I've read about the reviews of Wrestlemania, it was not a very impressive showing. I'd be interested to hear the opinions of the shareholders on this board what they thought about the event last night.